Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02926638
Status:
TERMINATED
Last Update Posted:
2020-03-19
First Post:
2016-05-06
Brief Title:
Lung-MAP Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-06-16
Start Date Type:
ACTUAL
Primary Completion Date:
2015-01-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10-12
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-06
First Submit QC Date:
October 4 2016
Study First Post Date:
2016-10-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2020-03-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-03-17
Last Update Post Date:
2020-03-19
Last Update Post Date Type:
ACTUAL